ClinicalTrials.gg
Status unknownNCT01142999BEEPUpdated Aug 5, 2011

Feasibility Study of Barrier Enhancement for Eczema Prevention

An interventional study of Sunflower oil and Control group in Eczema, sponsored by Oregon Health and Science University. Status unknown at 1 site in United States. Open to participants aged 1 Minute to 6 Months. Per ClinicalTrials.gov, last updated 2011-08-05.

Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Jun 2010), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
1 Minute to 6 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 252 studies in Eczema with a site in United States — 34 open to participants now, 48 under way, 9 of them phase 3. Eczema · United States.

Enrollment
145th of 217
46 · median 101
Started
2010
with 8 others
No phase
46 of 252
3 open now
Registered
31st of 252
by date

Among the 252 studies in Eczema with a site in United States, this one is the 145th largest by enrollment of the 217 interventional ones that give a count, is one of 9 that started in 2010, is one of 46 with no phase, and was the 31st registered.

Eczema

507 studies on the registry are indexed under Eczema; 91 are open to participants now.

Browse Eczema studies →

Open to participants now

34 of the 252 studies in Eczema with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 1 Minute to 6 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Eczema with a site in United States, or all of them as a file.
02

Study summary

The purpose of this protocol is to determine the feasibility of doing larger follow-up studies examining whether emollients used from birth can prevent eczema in high-risk babies and to help investigators find out if emollients (moisturizing skin creams) used from birth can prevent eczema in high-risk babies. Hypothesis: Enhancing the skin barrier from birth using emollients will prevent or delay the onset of eczema, especially in predisposed infants.

03

Conditions studied

  • Eczema

Browse trials for

04

Who can participate

Ages eligible
1 Minute to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must have a parent or sibling with a history of at least one of the following: eczema, allergic rhinitis or asthma
  2. Infant in overall good health
  3. Mother between the ages of 16 and 45 years of age at delivery; infant from birth thru 6 months of age
  4. Capable of giving

Exclusion criteria

Exclusion Criteria:

  1. Preterm birth defined as birth prior to 37 weeks gestation
  2. Major congenital anomaly
  3. Hydrops fetalis
  4. Significant dermatitis at birth not including seborrheic dermatitis ("cradle cap")
  5. Any immunodeficiency disorder or severe genetic skin disorder
  6. Any other serious condition that would make the use of emollients inadvisable
  7. Any other major medical problems that the investigator deems may increase the risk of adverse events with the intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Active comparator
    Intervention (moisturizer group)

    One group will be instructed to use a choice of 3 FDA-approved moisturizers and soap substitutes on their newborn infants.

    Drug: Sunflower oil · Drug: Aquaphor ointment · Drug: Cetaphil cream

  • Active comparator
    Control group (no moisturizers)

    This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.

    Drug: Control group

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of families willing to be randomized.

    Determine proportion of families willing to be randomized in order to design larger study in the future.

    Time frame: 6 months

Secondary outcomes

  1. Proportion of families eligible for the trial, willing to participate

    Time frame: 6 months

  2. Proportion of families who found the interventions acceptable

    Time frame: 6 months

  3. Reported adherence with intervention

    Time frame: 6 months

  4. Proportion of families for whom the blinding of the assessor to the allocation ostatus was not compromised

    Time frame: 6 months

  5. Amount of contamination as a result of increased awareness in the control group

    Time frame: 6 months

  6. Percentage of missing data and early withdrawal rates

    Time frame: 6 months

  7. Incidence of emollient-related adverse events

    Time frame: 6 months

  8. Incidence of eczema at 6 and 12 months

    Time frame: 12 months

  9. Age at onset of eczema

    Time frame: 6 months

  10. Filaggrin mutation status

    Time frame: 6 months

07

Study locations

1 site
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Aug 2011 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2010
First posted
Jun 14, 2010
Start
May 2010
Primary completionEst.
Aug 2011
CompletionEst.
Sep 2012
Last update
Aug 5, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01142999
First posted
Jun 14, 2010
Start date
May 2010
Primary completion
Aug 2011 (estimated)
Completion
Sep 2012 (estimated)
Last update
Aug 5, 2011

Study contacts

Eric L. Simpson, M.D., M.C.R.
principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sunflower Oil · Cetyl alcohol, propylene glycol, sodium lauryl sulfate non-lipid cleansing lotion

Start the discussion